Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes.

Fiche publication

Date publication

novembre 2023

Journal

Cardiovascular diabetology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Denimal D, Béland-Bonenfant S, Pais-de-Barros JP, Rouland A, Bouillet B, Duvillard L, Vergès B, Petit JM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37940926

Résumé

There is growing evidence that ceramides play a significant role in the onset and progression of non-alcoholic fatty liver disease (NAFLD), a highly prevalent condition in patients with type 2 diabetes associated with hepatic and cardiovascular events. However, the relationship between plasma ceramide levels and NAFLD severity in type 2 diabetes remains unclear. The main purpose of the present study was to investigate whether circulating levels of ceramides in patients with type 2 diabetes are associated with liver steatosis assessed by the highly accurate magnetic resonance imaging proton density fat fraction (MRI-PDFF). The secondary objective was to assess the relationship between plasma ceramides and noninvasive scores of liver fibrosis.